Recent studies presented at Technology and Heart Failure Therapeutics (THT) 2026 and simultaneously published in JACC, JACC: Heart Failure and JACC: Cardiovascular Interventions highlight advances in heart failure (HF) treatment:

• Sotatercept improves exercise tolerance in pulmonary arterial hypertension through mechanisms beyond the pulmonary vasculature, including increased hemoglobin.
• Baseline and early post‑procedure N-terminal pro-B-type natriuretic peptide levels help predict two‑year mortality or HF hospitalization after tricuspid edge-to-edge repair, offering a potential tool for risk stratification.
• Physician‑directed patient self‑management using ambulatory inferior vena cava‑based congestion monitoring proved feasible, increased timely interventions and showed favorable safety and clinical signals, supporting further evaluation in a randomized trial.